One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Patient Experience, Adverse Event Reporting, and Clinical Trial Design.
Neuman, Heather B. MD, MS 1,,
doi : 10.1200/JCO.23.01976
Volume 42(3) pgs. 247-368 January 20, 2024
Innovating Simpler and Less Toxic Frontline Management for Adults With ALL.
Logan, Aaron MD, PhD, MPhil 1,,
doi : 10.1200/JCO.23.01726
Chimeric Antigen Receptor (CAR) T-Cell Products for Pediatric Cancers: Why Alternative Development Paths Are Needed.
Rossig, Claudia MD 1,2,,; Pearson, Andrew D. MD 3,; Vassal, Gilles MD 3,4,; Scobie, Nicole 5; Bird, Nick 6; Blanc, Patricia 7; Vormoor, H. Josef MD 2,8; Calkoen, Friso G. MD 2; Locatelli, Franco MD, PhD 9,; Bufalo, Francesca del MD, PhD 9,10; Rives, Susana MD 11,12,; Jacoby, Elad MD 13,14,; Balduzzi, Adriana MD 15,16,; Bourquin, Jean-Pierre MD, PhD 17,; Baruchel, Andre MD 18,
doi : 10.1200/JCO.23.01314
MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2-Altered Advanced Solid Tumors.
Sweeney, Christopher J. MBBS 1,,; Hainsworth, John D. MD 2,3,; Bose, Ron MD, PhD 4,; Burris, Howard A. MD 2,3,; Kurzrock, Razelle MD 5,; Swanton, Charles FRCP, BSc, PhD 6,7,; Friedman, Claire F. MD 8,9,; Spigel, David R. MD 2,3,; Szado, Tania PhD 10,; Schulze, Katja PhD 10,; Price, Richard PhD 10,; Malato, Julia PhD 10,; Lo, Amy A. MD, MS 10,; Levy, Jonathan PhD 10,; Wang, Yong PhD 10,; Yu, Wei PhD 10,; Meric-Bernstam, Funda MD 11,
doi : 10.1200/JCO.22.02636
Importance of Low- and Moderate-Grade Adverse Events in Patients' Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 Trial.
O'Connell, Nathaniel S. PhD 1,; Zhao, Fengmin PhD 2,; Lee, Ju-Whei PhD 2; Ip, Edward H. PhD 1; Peipert, John Devin PhD 3,; Graham, Noah MB 2; Smith, Mary Lou JD, MBA 4,; Gareen, Ilana F. PhD 5; Carlos, Ruth C. MD 6,; Obeng-Gyasi, Samilia MD 7; Sparano, Joseph A. MD 8,; Shanafelt, Tait D. MD 9,; Thomas, Mary L. MSN 10; Cella, David PhD 3,; Wagner, Lynne I. PhD 1,; Gray, Robert PhD 2,
doi : 10.1200/JCO.23.00377
Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome-Negative B-Precursor ALL.
Stelljes, Matthias MD 1,,; Raffel, Simon MD 2,; Alakel, Nael MD 3,; Wasch, Ralph MD 4,; Kondakci, Mustafa MD 5; Scholl, Sebastian MD 6,; Rank, Andreas MD 7; Hanel, Mathias MD 8,; Spriewald, Bernd MD 9; Hanoun, Maher MD 10,; Martin, Sonja MD 11,; Schwab, Katjana MD 12; Serve, Hubert MD 13,; Reiser, Lena MSc 13; Knaden, Julian BSc 13; Pfeifer, Heike MD 13,; Marx, Julia MD 1; Sauer, Tim MD 2,; Berdel, Wolfgang E. MD 1,; Lenz, Georg MD 1,; Bruggemann, Monika MD 14,; Gokbuget, Nicola MD 13,; Wethmar, Klaus MD, PhD 1,
doi : 10.1200/JCO.23.00546
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial.
Westin, Shannon N. MD, MPH 1,,; Moore, Kathleen MD 2,; Chon, Hye Sook MD 3,; Lee, Jung-Yun MD 4,; Thomes Pepin, Jessica MD 5,; Sundborg, Michael MD 6,; Shai, Ayelet MD, PhD 7,; de la Garza, Joseph MD 8,; Nishio, Shin MD 9; Gold, Michael A. MD 10,; Wang, Ke MD 11; McIntyre, Kristi MD 12; Tillmanns, Todd D. MD 13,;
doi : 10.1200/JCO.23.02132
Economic Evaluation of a Nonmedical Financial Assistance Program on Missed Treatment Appointments Among Adults With Cancer.
Biddell, Caitlin B. PhD 1,2; Spees, Lisa P. PhD 1,2,; Trogdon, Justin G. PhD 1,2; Kent, Erin E. PhD 1,2; Rosenstein, Donald L. MD 2,3,; Angove, Rebekah S.M. PhD 4; Rogers, Cindy D. JD 2; Wheeler, Stephanie B. PhD, MPH 1,2,,
doi : 10.1200/JCO.23.00993
Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM).
Vasudev, Naveen S. MD, PhD 1,,; Ainsworth, Gemma MSc 2,; Brown, Sarah PhD 2,; Pickering, Lisa MD 3,; Waddell, Tom MD 4,; Fife, Kate MD 5,; Griffiths, Richard MD 6,; Sharma, Anand MD 7,; Katona, Eszter MA 2; Howard, Helen PhD 2; Velikova, Galina MD 1,; Maraveyas, Anthony MD 8,; Brown, Janet MD 9,; Pezaro, Carmel MD 10,; Tuthill, Mark MD 11,; Boleti, Ekaterini MD 12,; Bahl, Amit MD 13,; Szabados, Bernadett MD 14,; Banks, Rosamonde E. PhD 1,; Brown, Joanne BSc 1; Venugopal, Balaji MD 15,; Patel, Poulam MD 16,; Jain, Ankit MD 17; Symeonides, Stefan N. MD 18,; Nathan, Paul MD 7,; Collinson, Fiona J. MD 2,; Powles, Thomas MD 14,
doi : 10.1200/JCO.23.00236
SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer.
Rudin, Charles M. MD, PhD 1,,; Liu, Stephen V. MD 2,; Soo, Ross A. MD 3,; Lu, Shun MD 4,; Hong, Min Hee MD 5,; Lee, Jong-Seok MD 6; Bryl, Maciej MD 7,; Dumoulin, Daphne W. MD 8,; Rittmeyer, Achim MD 9,; Chiu, Chao-Hua MD 10,11,; Ozyilkan, Ozgur MD 12; Johnson, Melissa MD 13,; Navarro, Alejandro MD 14,; Novello, Silvia MD, PhD 15,; Ozawa, Yuichi MD 16,17,; Tam, Sammi Hiu PharmD, BCOP 18,; Patil, Namrata S. PhD 18,; Wen, Xiaohui MD 18,; Huang, Meilin PhD 18,; Hoang, Tien MD 18,; Meng, Raymond MD, PhD 18,; Reck, Martin MD 19,
doi : 10.1200/JCO.23.01363
Cumulative Absolute Risk of Subsequent Colorectal Cancer After Abdominopelvic Radiotherapy Among Childhood Cancer Survivors: A PanCareSurFup Study.
Heymer, Emma J. PhD 1; Jozwiak, Katarzyna PhD 2; Kremer, Leontien C. MD, PhD 3,4; Winter, David L. HNC 1; de Vathaire, Florent PhD 5; Sunguc, Ceren PhD 1; Sugden, Elaine MD 1; Kok, Judith L. PhD 3; van der Pal, Helena J.H. MD 3; Hjorth, Lars MD, PhD 6,; Jakab, Zsuzsanna MD 7; Maule, Milena M. PhD 8; Haupt, Riccardo MD 9; Bagnasco, Francesca PhD 10; Terenziani, Monica MD 11; Diallo, Ibrahima PhD 5; Gunnes, Maria W. PhD 12,13,; Sommer, Grit PhD 14,; Zadravec Zaletel, Lorna MD 15; Kuehni, Claudia E. PhD 14,16,; Winther, Jeanette F. PhD 17,18; Lahteenmaki, Paivi M. MD 19; Gudmundsdottir, Thorgerdur MD 17,20; Allodji, Rodrigue S. PhD 5; Skinner, Roderick MD, PhD 21,; Ronckers, Cecile M. PhD 3,22; Hawkins, Michael M. DPhil 1; Reulen, Raoul C. PhD 1; Teepen, Jop C. PhD 3,
doi : 10.1200/JCO.23.00452
Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study.
Lee, Choong-kun MD, PhD 1,2,; Kim, Hyo Song MD, PhD 1,2; Jung, Minkyu MD, PhD 1,2,; Kim, Hyunki MD, PhD 3; Bae, Woo Kyun MD, PhD 4; Koo, Dong-Hoe MD, PhD 5; Jeung, Hei Cheul MD, PhD 6; Park, Sook Ryun MD, PhD 7,; Hwang, In Gyu MD, PhD 8; Zang, Dae Young MD, PhD 9; Lee, Hyun Woo MD 10; Park, Sejung PhD 2; Nam, Chung Mo PhD 11; Chung, Hyun Cheol MD, PhD 1,2,; Rha, Sun Young MD, PhD 1,2,12,,
doi : 10.1200/JCO.23.00971
ASCO Ethical Guidance for the Practical Management of Oncology Drug Shortages.
Hantel, Andrew MD 1,; Spence, Rebecca JD, MPH 2,; Camacho, Polo PhD 2; Bradbury, Angela R. MD 3,; Denburg, Avram E. MD 4; Jagsi, Reshma MD, DPhil 5,; Moy, Beverly MD, MPH 1; Rathmell, W. Kimryn MD 6,; Rosenberg, Abby R. MD, MS, MA 1; Symington, Banu MD 7; Marron, Jonathan M. MD, MPH 1,; Peppercorn, Jeffrey MD, MPH 8,
doi : 10.1200/JCO.23.01941
Assessing Predictability of Pathologic Lymph Node Regression for Recurrence and Survival in Esophageal Adenocarcinoma.
Sun, Ryan PhD; Liu, Jingyi PhD; Wei, Lee-Jen PhD
doi : 10.1200/JCO.23.01785
Reply to R. Sun et al.
Moore, Jonathan L. FRCS; Santaolalla, Aida PhD; Van Hemelrijck, Mieke PhD; North, Bernard PhD; Davies, Andrew R. MD, FRCS
doi : 10.1200/JCO.23.02131
